Enterprise Value

47.1M

Cash

205.4M

Avg Qtr Burn

-57.74M

Short % of Float

12.00%

Insider Ownership

14.40%

Institutional Own.

62.64%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details
Rare diseases, Hemophilia, Rare genetic disease, Blood disorder

Phase 3

Data readout

TX-200 Details
Kidney disease, Kidney transplantation

Phase 1/2

Interim update

ST-920 (isaralgagene civaparvovec) Details
Fabry disease, Rare genetic disease

Phase 1/2

Update

BIVV003 (SAR445136) Details
Sickle cell disease, Blood disorder

Failed

Discontinued

ST-400 Details
Blood disorder, Beta thalessemia

Failed

Discontinued

SB-913 Details
Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II

Failed

Discontinued